| Management target | Revenue 25.0% FY27 |
|---|
| Revenue growth | Q2 -55% YoY; H1 -2% YoY (revenue from operations) |
|---|---|
| Margins | Q2 EBITDA 18.8% vs 29.0%; H1 22.7% vs 22.5% |
| Demand visibility | Q2 devices 395 vs 647; kits 3.2Mn vs 8.7Mn YoY |
| Management confidence | Reiterates 25% FY27 target; Q2 described as softer |
Growth
Q2 revenue ₹259.0 Cr vs ₹580.3 Cr; EBITDA margin 18.8% vs 29.0%. H1 revenue ₹667.4 Cr vs ₹680.0 Cr; EBITDA flat at ₹153 Cr.
Outlook
Reiterates FY27 25% topline growth target; H1 historically 35–45% of annual revenue. No capex quantified.
Risks
Q2 softness from rate-contract negotiations. Q2 kit volumes down 63% YoY; depreciation up 70%; Q2 finance costs up 27%.
Last quarter's promises, checked
Partly delivered
- ₹72Cr automation + ~₹105Cr Bangalore R&D → H1 investing ₹141Cr, split undisclosed (= PARTIAL)
- Prognosys ~19% FY27 EBITDA → not disclosed (= PARTIAL)
Missed
- FY27 topline ~25% → H1 ₹667Cr, -2% YoY (= MISS, H1 run-rate)
- FY27 EBITDA 24-25% → H1 22.7%; Q2 18.8% (= MISS, H1 run-rate)
- FY27 devices 2,200-2,600 → Q1 164 + Q2 395 (= MISS, H1 run-rate)
Investor Presentation filed with BSE, NSE: MOLBIO. Summary written with AI assistance from the document.
Molbio Diagnostics Ltd: key numbers
- Share price
- ₹1,339.30
- Market cap
- ₹15,434 Cr
- Revenue (annual)
- ₹1,446 Cr
- Net profit (annual)
- ₹166.6 Cr
- P/E (TTM)
- 100.0×Sector 53.9×
- Promoter holding
- 41.29%
- FII holding
- 1.59%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Molbio Diagnostics Ltd
All →Molbio Diagnostics Other Announcement
Molbio Diagnostics filed CRISIL's monitoring agency report on IPO proceeds utilisation for the quarter ended 30 September 2026. The report states no deviation from the issue objects.
Molbio Diagnostics Q2 FY27 Results: Net Profit ₹7.7 Cr, Down 92.8% YoY
Molbio Diagnostics Ltd reported revenue from operations of ₹259 Cr (-55.4% YoY) and net profit of ₹7.7 Cr (-92.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹7.7 Cr · -92.8% YoY
Molbio Diagnostics Board Meeting Date
Molbio Diagnostics' Board is scheduled for November 5, 2026, to approve Q1 and H1 results. Trading window stays closed until 48 hours post-declaration.
Molbio Diagnostics Price Movement Clarification
Molbio Diagnostics responded to NSE's spurt-in-volume query, stating the movement is purely market-driven. No pending price-sensitive information is slated for disclosure.
Molbio Diagnostics Other Announcement
Molbio Diagnostics Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure provides information on promoter and public shareholding structures.
Molbio Diagnostics Capital Structure Change
Kotak Mahindra Mutual Fund acquired 5,70,000 Molbio Diagnostics shares in the open market on 08 October 2026. Its stake crossed 5% to 5.4834%.